NxStage Medical Inc (NXTM.OQ)
NXTM.OQ on NASDAQ Stock Exchange Global Select Market
25.73USD
23 Apr 2018
25.73USD
23 Apr 2018
Change (% chg)
$0.23 (+0.90%)
$0.23 (+0.90%)
Prev Close
$25.50
$25.50
Open
$25.53
$25.53
Day's High
$25.73
$25.73
Day's Low
$25.45
$25.45
Volume
45,809
45,809
Avg. Vol
152,953
152,953
52-wk High
$30.80
$30.80
52-wk Low
$20.47
$20.47
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Hold | 0.00 | December | 24 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 1 | 1 | 0 | 0 |
| (2) OUTPERFORM | 0 | 0 | 0 | 1 |
| (3) HOLD | 5 | 6 | 8 | 8 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.67 | 2.71 | 3.00 | 2.89 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 3 | 106.36 | 107.90 | 105.34 | 111.85 |
| Quarter Ending Sep-18 | 3 | 107.96 | 109.80 | 105.92 | 115.26 |
| Year Ending Dec-18 | 5 | 434.02 | 443.05 | 426.00 | 459.19 |
| Year Ending Dec-19 | 4 | 491.60 | 521.54 | 466.20 | 545.11 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 4 | 0.00 | 0.02 | -0.04 | 0.03 |
| Quarter Ending Sep-18 | 4 | -0.00 | 0.02 | -0.06 | 0.04 |
| Year Ending Dec-18 | 5 | -0.01 | 0.08 | -0.20 | 0.16 |
| Year Ending Dec-19 | 4 | 0.14 | 0.25 | -0.10 | 0.51 |
| LT Growth Rate (%) | 1 | 20.00 | 20.00 | 20.00 | 20.00 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 102.76 | 103.60 | 0.84 | 0.82 |
| Quarter Ending Sep-17 | 101.72 | 97.29 | 4.43 | 4.35 |
| Quarter Ending Jun-17 | 96.50 | 96.22 | 0.29 | 0.30 |
| Quarter Ending Mar-17 | 95.29 | 96.83 | 1.54 | 1.61 |
| Quarter Ending Dec-16 | 92.05 | 93.01 | 0.97 | 1.05 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | -0.00 | -0.03 | 0.02 | -500.00 |
| Quarter Ending Sep-17 | -0.00 | -0.14 | 0.14 | -10,669.23 |
| Quarter Ending Jun-17 | -0.02 | -0.03 | 0.01 | -27.12 |
| Quarter Ending Mar-17 | -0.02 | -0.02 | 0.00 | -9.91 |
| Quarter Ending Dec-16 | -0.02 | -0.02 | 0.00 | -5.21 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 106.36 | 106.36 | 106.36 | 106.84 | 111.85 |
| Quarter Ending Sep-18 | 107.96 | 107.96 | 107.96 | 109.03 | 115.26 |
| Year Ending Dec-18 | 434.02 | 434.02 | 434.02 | 440.69 | 459.19 |
| Year Ending Dec-19 | 491.60 | 491.60 | 491.60 | 489.89 | 545.11 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
| Quarter Ending Sep-18 | -0.00 | -0.00 | -0.00 | 0.02 | 0.04 |
| Year Ending Dec-18 | -0.01 | -0.01 | -0.01 | 0.08 | 0.16 |
| Year Ending Dec-19 | 0.14 | 0.14 | 0.14 | 0.28 | 0.51 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- Four charged with trading on U.S. health agency leaks face trial
- BRIEF-Alpine Associates Management Reports 6.09 Pct Passive Stake In NxStage Medical
- Prospect of tougher antitrust regulation worries deal investors
- Prospect of tougher antitrust regulation worries deal investors
- Prospect of tougher antitrust regulation worries deal investors